Comment on: Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir [2]

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 1, 2006, Pages 220-221

  Anderson, Peter L ^a   Kakuda, Thomas N ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b Tibotec Inc   (United States)

Author keywords

Drug interactions; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ABACAVIR; ADENOSINE DERIVATIVE; CYTIDINE DERIVATIVE; DIDANOSINE; HYDROXYUREA; LAMIVUDINE; METHOTREXATE; NUCLEOSIDE ANALOG; PURINE DERIVATIVE; PURINE NUCLEOSIDE PHOSPHORYLASE; RIBAVIRIN; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; ZIDOVUDINE;

CD4+ T LYMPHOCYTE; CLINICAL PROTOCOL; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LYMPHOCYTE DEPLETION; MONOTHERAPY; NONHUMAN; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION;

ADENINE; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; HIV INFECTIONS; HUMANS; PHOSPHONIC ACIDS; PURINE-NUCLEOSIDE PHOSPHORYLASE;

EID: 33748052984     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl203     Document Type: Letter

References (9)

1. Barreiro P, Soriano V. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother 2006; 57: 806-9.
2. Kakuda TN, Anderson PL, Becker SL. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. AIDS 2004; 18: 2442-4.
3. Hawkins T, Veikley W, St Claire RL 3rd et al. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 2005; 39: 406-11.
4. Vela JE, Miller MD, Rhodes GR et al. Effect of tenofovir in combination with other anti-HIV NRTIs on intracellular nucleotide pools. In: Programs and Abstracts of the Forty-fifth Interscience Conference Antimicrobial Agents and Chemotherapy, Washington, DC, USA, 2005. Poster H1901, p. 292. American Society for Microbiology, Washington, DC, USA.
5. Lanier ER, Hazen R, Ross L et al. Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1. J Acquir Immune Defic Syndr 2005; 39: 519-22.
6. Ray AS. Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. AIDS Rev 2005; 7: 113-25.
7. Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis 2004; 38: 743-53.
8. Robbins BL, Wilcox CK, Fridland A et al. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 2003; 23: 695-701.
9. Kuritzkes DR. Less than the sum of its parts: Failure of a tenofovir-abacavir-lamivudine triple-nucleoside regimen. J Infect Dis 2005; 192: 1867-8.